IPO Databook: Actuate Therapeutics (ACTU US) - Oct 2026

81 Views08 Oct 2026 10:04

SUMMARY

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company developing elraglusib for high impact, difficult to treat cancers by inhibiting GSK-3.
Elraglusib's Phase 2 study in mPDAC met its primary endpoint, demonstrating increased median overall survival and 12-month survival rate.
The company has incurred significant operating losses and negative cash flows, requiring additional financing to fund operations.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream